Patents by Inventor James B. Hoffman

James B. Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8071592
    Abstract: Bicyclic nitrogen containing compounds and their use as antibacterials.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: December 6, 2011
    Assignee: Glaxo Group Limited
    Inventors: Lluis Ballell, David Barros, Gerald Brooks, Julia Castro Pichel, Steven Dabbs, Robert A Daines, David Thomas Davies, Jose Maria Fiandor Roman, Israil Pendrak, Modesto J Remuiñan Blanco, Jason Anthony Rossi, Ilaria Giordano, Alan Joseph Hennessy, James B Hoffman, Graham Elgin Jones, Timothy James Miles, Neil David Pearson, Lihua(lily) Zhang
  • Publication number: 20090270374
    Abstract: Bicyclic nitrogen containing compounds and their use as antibacterials.
    Type: Application
    Filed: July 18, 2007
    Publication date: October 29, 2009
    Inventors: Llius Ballell, David Barros, Gerald Brooks, Julia Castro Pichel, Steven Dabbs, Robert A. Daines, David Thomas Davies, Jose Maria Fiandor Roman, Israil Pendrak, Modesto J. Remuinan Blanco, Jason Anthony Rossi, Ilaria Giordano, Alan Joseph Hennessy, James B. Hoffman, Graham Elgin Jones, Timothy James Miles, Neil David Pearson, Lihua(lily) Zhang
  • Patent number: 6562840
    Abstract: The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1—R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: May 13, 2003
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Juan José Marugán
  • Patent number: 6515002
    Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: February 4, 2003
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Roger F. Bone, Scott L. Klein, Troy L. Randle
  • Patent number: 6492403
    Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4, X, Y and Z are defined in the specification.
    Type: Grant
    Filed: February 9, 2000
    Date of Patent: December 10, 2002
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Roger F. Bone, Scott L. Klein, Troy L. Randle
  • Patent number: 6403633
    Abstract: The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: June 11, 2002
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Juan José Marugán
  • Publication number: 20020037915
    Abstract: Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1
    Type: Application
    Filed: September 26, 2001
    Publication date: March 28, 2002
    Applicant: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Roger F. Bone, Scott L. Klein, Troy L. Randle
  • Publication number: 20010031781
    Abstract: The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.
    Type: Application
    Filed: April 10, 2001
    Publication date: October 18, 2001
    Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Juan J. Marugan
  • Patent number: 6291514
    Abstract: The present invention is directed to compounds of Formula I: wherein X is O, S or NR7 and R1-R7, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: September 18, 2001
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Carl R. Illig, Nalin L. Subasinghe, James B. Hoffman, Kenneth J. Wilson, M. Jonathan Rudolph, Juan José Marugán
  • Patent number: 5648352
    Abstract: The invention is directed to a series of novel piperazinylcamphorsulfonyl compounds where the camphor ring is substituted by amides, amines, alkanes, alkenes, alkylamines, halogens, hydroxy, carboxy, alkoxycarbonyl and heterocyclic tings. Such compounds are oxytocin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: July 15, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Jill M. Erb, Doug W. Hobbs, James B. Hoffman, Joseph M. Pawluczyk, Debra S. Perlow, Daniel F. Veber, Peter D. Williams
  • Patent number: 5204349
    Abstract: Compounds of the formula: ##STR1## where R.sup.1 is hydrogen or hydroxy and R.sup.2 is a substituted amino group, a substituted heterocyclic ring or a substituted alkyl. These compounds are oxytocin and vasopressin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery, timing of parturition, uterine hyperactivity, endometriosis, hypertension, congestive heart failure, hyponatremia and cognitive disorders. Also disclosed are pharmaceutical compositions containing these compounds, methods of their use and methods of their preparation.
    Type: Grant
    Filed: September 16, 1991
    Date of Patent: April 20, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger, Kevin Gilbert, Doug W. Hobbs, James B. Hoffman, George F. Lundell, Douglas J. Pettibone